Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06618274 · ClinicalTrials.gov registry record · NA
Effectiveness of Central Oncology Navigation and the Use of an ORN
A NA study of Cancer and Malignant Tumor, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 686
- Enrollment target
- 1
- Study location
NCT06618274: Recruiting NA study of Cancer and Malignant Tumor, sponsored by UNC Lineberger Comprehensive Cancer Center.
NCT06618274 is a NA study of Cancer and Malignant Tumor that is actively recruiting participants, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 686 participants, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06618274, a NA study of Cancer and Malignant Tumor, is actively recruiting participants, sponsored by UNC Lineberger Comprehensive Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 686 participants
- Enrollment target
- 1
- Study location
Study Summary
This health services interventional study investigates the effectiveness of central oncology navigation (SOC ) alone and central oncology navigation with a new role called an "oncology research navigator (ORN)" who is embedded in central oncology navigation cancer care delivery. This study will examine two patient cohorts: Cohort 1 will enroll patients with new cancer appointments within genitourinary (GU) or thoracic cancers. These clinics have not yet implemented the central navigation program. Participants will be enrolled pre- and post-implementation of the central oncology navigator within these cancer groups to evaluate the effectiveness of the central oncology navigator alone. The second cohort will enroll participants with new cancer appointments within gastrointestinal (GI), hematology, and breast cancer (clinics where the central navigation program was implemented). These individuals will be randomized to receive standard of care, which for these cancer types includes central oncology navigation or the intervention of an oncology research navigator in addition to SOC. This intervention will involve baseline and biweekly follow-up for a total of 3 months. Interactions with the ORN will include facilitating participation in supportive care services and clinical trials. All participants will undergo baseline and follow-up patient-reported outcomes and data collection. The study will evaluate the impact of the central oncology navigation program alone, as well as the addition of the ORN on patient quality of life, as well as enrollment into studies and participation in supportive care services. Additional analyses will evaluate the impact of the central oncology navigation program on patient experience, patient activation, net promoter scores, and overall survival.
Primary Outcome
Participation in at least 1 supportive service offered will be measured by the number of patients receiving services. This information will be gathered from chart review.
Conditions Studied
Interventions
- BEHAVIORAL Intervention of oncology research navigator embedded in central oncology navigation
- BEHAVIORAL Central oncology navigation (SOC)
Study Locations (1)
North Carolina
- UNC Lineberger Comprehensive Cancer Center - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 686 participants |
| Start Date | 2025-03-03 |
| Est. Completion | 2031-07-01 |
| Phase | NA |
What NCT06618274 shows while recruiting
NCT06618274 is an interventional study that assigns participants to a tested intervention. The registered 686 participants enrollment target is mid-sized for trials with a published cap, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (80% lower).
The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which Intervention of oncology research navigator embedded in central oncology navigation is the first listed.
NCT06618274 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT06618274 about?
NCT06618274 is a clinical study titled "Effectiveness of Central Oncology Navigation and the Use of an ORN". This health services interventional study investigates the effectiveness of central oncology navigation (SOC ) alone and central oncology navigation with a new role called an "oncology research navigator (ORN)" who is embedded in central oncology navigation cancer care delivery. This study will exam...
What is the current status of trial NCT06618274?
This trial is currently recruiting. It is a NA study. The enrollment target is 686 participants. The study started on 2025-03-03. Estimated completion is 2031-07-01.
What conditions does trial NCT06618274 study?
This clinical trial studies the following conditions: Cancer, Malignant Tumor.
What interventions are being tested in trial NCT06618274?
The interventions under investigation include: Intervention of oncology research navigator embedded in central oncology navigation (BEHAVIORAL), Central oncology navigation (SOC) (BEHAVIORAL).
Who is sponsoring clinical trial NCT06618274?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06618274 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06618274's enrollment target sits among peer trials
686 104th of 615 higher than 512 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
BfedBwell Optimization Pilot
RECRUITING · NA
-
Legal Evaluation for Greater Access to Cancer Care (LEGAL-CARE)
RECRUITING · NA
-
Optimizing the AYA Survivors' Coping and Emotional Needs Toolkit
RECRUITING · NA
-
Comprehensive Connected Cancer Care (C4): Intervention Evaluation
RECRUITING · NA
-
Cancer-related Fatigue and Its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele-exercise Intervention
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04333537 · 686 participants · Phase 2
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
- NCT06459180 · 686 participants · Phase 3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
- NCT06899126 · 686 participants · Phase 3
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
- NCT05099770 · 685 participants · Phase 3
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI